iPSC Reprogramming Using Peripheral Blood Mononuclear Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating immune cells from somatic cells are cumbersome and inconvenient, requiring skin biopsies and labor-intensive cell culture systems, with a need for more accessible and efficient methods to produce patient-specific immune cells like T cells, NK cells, and dendritic cells.
Innovation Solution
A method involving the reprogramming of somatic cells, such as blood cells, into induced pluripotent stem cells (iPSCs) followed by differentiation into hematopoietic precursor cells (HPCs) and subsequent culture under specific conditions to produce immune cells, including T cells, NK cells, and dendritic cells, using reprogramming factors like Sox2, Oct4, cMyc, Klf4, Nanog, and Lin28, and cytokines such as BMP4, VEGF, and IL-3, under defined media conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If skin biopsies and fibroblast cell expansion are used to generate iPSCs, then patient-specific stem cells can be produced, but the process becomes cumbersome and labor-intensive
Solution Approach 1:
The patent extracts and eliminates the need for skin biopsies and fibroblast expansion by using peripheral blood mononuclear cells (PBMCs) as the starting material. PBMCs can be obtained through simple blood draws and do not require complex culture systems for expansion, thereby simplifying the overall process while maintaining patient-specificity
Solution Approach 2:
The patent uses PBMCs as a surrogate source that copies the essential requirement of obtaining patient-specific cells without requiring the complex skin biopsy and fibroblast expansion process. PBMCs serve as an alternative template that can be directly reprogrammed without the intermediate steps needed for skin-derived cells
2Reliability
If somatic cells are obtained directly from human subjects, then reprogramming can be performed, but the process becomes inconvenient and requires complex procedures
Solution Approach 1:
The patent extracts the inconvenient aspect of direct somatic cell acquisition by using PBMCs from peripheral blood as an alternative source. Blood samples can be collected through simple venipuncture procedures and stored or transferred easily, eliminating the need for complex skin biopsies or direct tissue sampling
Solution Approach 2:
The patent introduces PBMCs as an intermediary cell type that bridges the gap between convenient blood sampling and effective reprogramming. PBMCs serve as a accessible intermediate source that can be obtained through simple blood draws and then reprogrammed to generate patient-specific iPSCs
3Ease of operation
If blood samples are collected and stored for iPSC generation, then accessibility and convenience are improved, but additional storage and distribution infrastructure is required
Solution Approach 1:
The patent utilizes PBMCs as a disposable, easily obtainable cell source that can be collected in standard blood collection kits. The cells can be processed immediately or stored at standardized locations without requiring specialized infrastructure, making the system more practical and less complex
4Reliability
If conventional methods are used to generate immune cells, then existing protocols can be followed, but the process is time-consuming and less efficient
Solution Approach 1:
The patent performs preliminary reprogramming of PBMCs into iPSCs before differentiation into immune cells. This preliminary action creates a versatile platform that can be differentiated into multiple immune cell types (T cells, NK cells, dendritic cells) through standardized protocols, improving overall efficiency and productivity
Data Source
AI summary
Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.